Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 441-420-8 | CAS number: 113889-23-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No experimental toxico-kinetic data are available for assessing absorption, distribution, metabolism and excretion of the substance. Based on effects seen in the human health toxicity studies and physico-chemical parameters Cyclobutanate is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
Cyclobutanate and the assessment of its toxico-kinetic behaviour
Introduction: The test material Cyclobutanate is a butyl ester attached to a tricyclodecenyl fused ring structure. It is a clear colourless liquid with a molecular weight of 220 that does not preclude absorption. The test material may show some hydrolysis in alkaline conditions rather than in acidic conditions because it is an ester. The substance has a low volatility: 11.2 Pa.
Absorption
Oral: The results of the repeat dose oral toxicity show that the substance is being absorbed by the gastro-intestinal tract following oral administration, because non-adverse alpha-hydrocarbon nephropathy specific for the male rate was seen. The relatively low molecular weight and the moderate octanol/water partition coefficient (Log Kow 4.48) and water solubility (11.5 mg/l) would favour absorption through the gut. According to Martinez and Amidon (2002) the optimal log Kow for oral absorption falls within a range of 2-7. This shows that Cyclobutanate is likely to be absorbed orally and therefore the oral absorption is expected to be >> 50%.
Skin: Based on the physico-chemical characteristics of the substance, being a liquid, its molecular weight (220), log Kow (4.48) and water solubility (11.5), indicate that (some) dermal absorption is likely to occur. The optimal MW and log Kow for dermal absorption is < 100 and in the range of 1-4, respectively (ECHA guidance, 7.12, Table R.7.12-3). Cyclobutanate is just outside optimal range and therefore the skin absorption is not expected to exceed the oral route.
Lungs: Absorption via the lungs is also indicated based on these physico-chemical properties. Though the inhalation exposure route is thought minor, because of its low volatility (11.2 Pa), the octanol/water partition coefficient (4.48), indicates that inhalation absorption is possible. The blood/air (BA) partition coefficient is another partition coefficient indicating lung absorption. Buist et al. 2012 have developed BA model for humans using the most important and readily available parameters:
Log PBA = 6.96 – 1.04 (Log VP) – 0.533 (Log Kow) – 0.00495 MW.
For Cyclobutanate the B/A partition coefficient would result in:
Log P (BA) = 6.96- 1.04 x (1.04) – 0.533 x 4.48 – 0.00495 x 220= 2.4
This means that Cyclobutanate has a tendency to go from air into the blood. It should, however, be noted that this regression line is only valid for substances which have a vapour pressure > 100 Pa. Despite Cyclobutanate being somewhat out of the applicability domain and the exact B/A may not be fully correct, it can be seen that the substance will be readily absorbed via the inhalation route and may be close to 100%.
Distribution
The moderate water solubility of the test substance would limit distribution in the body via the water channels. The log Kow would suggest that the substance would pass through the biological cell membrane. Due to metabolization, presented below, the substance as such would not accumulate in the body fat.
Metabolism
There are no actual data on the metabolisation of Cyclobutanate in mammals. Hydrolysis is limitedly seen: at pH4 and pH7 no hydrolysis occurs. At pH 9 the half-life was 13 days at 25oC. Small chain straight alkyl (C4) esters such as this substance will be fully metabolised in the gut and liver into the respective Cycla-alcohol (3385-61-3) and butanoic acid (107-92-6) (fig. 1). This can be done by micro-organisms in the gut (Imai and Ohare, 2010) and/or human carboxylesterase (hCE-2) in the liver (WHO, 2006, White et al. 1990 as presented by EFSA (2008). EFSA uses Cyclandalate (456-59-7) metabolism as an example for de-esterification and formation of a secondary alcohol.
The Cycla-alcohol metabolite found in the biodegradation study with Cyclobutanate support the degradation of the ester by micro-organism (see biodegradation section, additional information). The “Cycla-alcohol” is too bulky to be further cleaved in the mitochondrion and needs glucuronidation for excretion (EFSA, 2008) (Fig. 1). Another pathway of excretion is seen in male rat which is via alpha 2u-globulin. Butanoic acid can be metabolised and be used as energy source or building block (EFSA, 2008 referencing Nelson and Cox, 2000a).
Fig. 1 Cyclobutanate metabolises into the alcohol (3385-61-3) and butanoic acid (107-92-6). Thereafter Cyclobutanate will be glucuronidated and butanoic acid will be further metabolises in mitochondrion.
Air-breathing organisms: These organisms may bioaccumulate substances which are limitedly metabolised (Gobas et al., 2020). This would leave excretion via the lungs as the key route. For substances with log Kow > 2 (and Koa 5), this may result in bioaccumulation. The presented metabolism for Cyclobutanate results in ester cleavage, glucuronidation, and excretion via the urine. The glucuronidated Cycla-alcohol has a low log Kow because glucuronic acid has a low log Kow – 1.87 (Pubmed). This log Kow presents absence of bioaccumulation in air-breathing organism. Gobas et al., 2020, figure 6, D, show that oxygen containing substances in general are no concern for air-breathing organism due to Phase 1 and/or Phase 2 (conjugation e.g. by glucuronidation) pathways.
Excretion
Glucuronidation of the substance or its metabolite will result in excretion in the kidneys. Effects seen in the kidney of the male rats (alpha 2u globulin hydrocarbon nephropathy) also show that excretion is through the urine. Any unabsorbed substance will be excreted via the faeces.
Discussion:
Cyclobutanate is expected to be readily absorbed, orally and via inhalation, based on the human toxicological information and physico-chemical parameters. The substance also is expected to be absorbed dermally based on the physic-chemical properties. The MW and the log Kow are higher than the favourable range for dermal absorption but significant absorption is likely.
In absence of any human health hazard there is no DNEL derivation needed and therefore no route to route extrapolation.
Conclusion
Cyclobutanate is expected to be readily absorbed via the oral and inhalation route and somewhat lower via the dermal route based on toxicity and physico-chemical data. Using the precautionary principle for route to route extrapolation the final absorption percentages derived are: 50% oral absorption, 50% dermal absorption and 100% inhalation absorption.
In absence of any human health hazard there is no route to route extrapolation needed.
References
Buist, H.E., Wit-Bos de, L., Bouwman, T., Vaes, W.H.J., 2012, Predicting blood:air partition coefficient using basic physico-chemical properties, Regul. Toxicol. Pharmacol., 62, 23-28.
EFSA, 2008, Scientific opinion on Flavouring groups evaluation, 47, (FGE.47), Bicyclic secondary alcohols, ketones and related esters form chemical group 8, Scientific opinion of the panel on food additives, flavouring, processing aids and materials in contact with food, https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2008.743: See Annex 3 for references on carboxylesterases; Heymann, 1980 and White et al, 1990.
EFSA, 2012, (FGE.87Rev1): Consideration of bicyclic secondary alcohols, ketones and related esters evaluated by JECFA (63rd meeting) structurally related to bicyclic secondary alcohols, ketones and related esters evaluated by EFSA in FGE.47 (2008), EFSA Journal 2012, 10(2), 2564. Follow up of the more elaborated EFSA, 2008 review.
Gobas, F.A.P.C., Lee, Y-S, Lo, J.C., Parkerton, T.F., Letinskid, D.J., 2020, A Toxicokinetic Framework and Analysis Tool for Interpreting Organisation for Economic Cooperation and Development Guideline 305 dietary bioaccumulation test, Environ. Toxicol. Chem., 39, 171-188.
Imai and Ohare, 2010, The role of intestinal carboxylesterase in the oral absorption of prodrugs, Curr Drug Metab,11, 793-805.
Martinez, M.N., And Amidon, G.L., 2002, Mechanistic approach to understanding the factors affecting drug absorption: a review of fundament, J. Clinical Pharmacol., 42, 620-643.
IGHRC, 2006, Guidelines on route to route extrapolation of toxicity data when assessing health risks of chemicals, http://ieh.cranfield.ac.uk/ighrc/cr12[1].pdf
White, D.A., Heffron, F., Miciak, A., Middleton, B., Knights, S., Knight, D., 1990. Chemical synthesis of dual radiolabelled cyclandelate and its metabolism in rat hepatocytes and mouse J774 cells. Xenobiotica 20(1), 71-79.
WHO, 2006, Food Additive Series 54, Safety evaluation of certain food additives, http://www.inchem.org/documents/jecfa/jecmono/v54je01.pdf; page 385 and 399 and 400, of the report.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.